Tag Archives: Bristol-Myers Squibb

How 6 Big Pharma Companies Use Twitter to Engage with Audiences

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

Pharma companies have begun to embrace different communication channels, including social media, to promote their products, present their drug development initiatives and engage with audiences worldwide.

However, make no mistake, social media is not the same for pharma companies as it is for regular users. Without proper planning, controls and staff training, firms risk fines, sanctions and worse, damage to their reputation.

Facebook, Twitter and Pinterest are the main online networks that pharmaceutical companies are eyeing. In this article, we’ll take a look at how pharma companies like Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Novartis use Twitter to maintain a close connection with their existing and potential patients.

 

Bristol-Myers Squibb

Screen Shot 2017-06-13 at 09.23.23

@bmsnews is the name of New York-based Bristol-Myers Squibb’s Twitter account. The latter was opened in April 2009 and has now has 108.000 followers. The company’s Twitter feed covers everything from drug research results and analysis, clinical collaborations with other pharma companies, to features about the company’s supply chain, and many more.

 

AstraZeneca

Screen Shot 2017-06-13 at 09.24.44

Apart from the main @AstraZeneca Twitter account, the company also has accounts for different countries (UK, US, Canada, etc) and a Twitter profile dubbed @AZhelps. The latter is destined to help people manage and support their health more confidently. The account was opened in 2009 and it currently has over 3000 followers. On the official company account, AstraZeneca posts articles and press releases related to drug discovery, tweets from different conferences, research data, etc. The account now boasts 126.000 followers.

 

GlaxoSmithKline

Screen Shot 2017-06-13 at 09.26.15

@GSK was one of the first pharma companies to be on Twitter. They created their account 10 years ago, in 2007, and now have 146.000 followers. The UK-based company also has a US version @GSKUS that it started in March 2009 and has 73.800 followers. They post R&D updates, info about conferences and events that they’re attending, studies, interviews with patients and employees, etc.

 

Pfizer

Screen Shot 2017-06-13 at 09.27.12

Apart from having separate Twitter accounts for countries like Belgium, France, Turkey, Germany, Austria, etc, @pfizer has an official Twitter profile started in 2009 which now has 206.000 followers and a channel dedicated to media announcements and investor communications dubbed @pfizer_news. Pfizer’s Twitter account is the most followed of all the big pharma Twitter accounts. It mainly focuses on the company’s initiatives in the greater therapeutic arena (like the #QuitSmoking one), cancer research, health tips, polls and surveys, etc.

 

Sanofi

Screen Shot 2017-06-13 at 09.28.33

@sanofi created its official Twitter profile in 2009 and now has 92.600 followers. The French pharma company has more than 18 Twitter accounts. It has handles for different regions – France, Canada, and the US, as well as accounts for different units like its diabetes franchise and its Genzyme unit. On the company’s official Twitter feed you can find posts related to Big Data and health initiatives, collaborations with startups to develop new health solutions, their anti counterfeiting initiatives, vaccines research and development, etc.

 

Novartis

Similar to the other pharma companies, Novartis has several Twitter handles, one for each division of the company (@NovartisPharma for the pharmaceutical division, @NovartisScience, @NovartisCancer) as well as the official page @Novartis. The latter was created in 2008 and has 216.000 followers.

Also, Novartis has one account devoted entirely to oncology clinical trials @NovartisOncCT that allows patients to find out if they qualify for trials.

On their general Twitter account, they update their audience on the latest drug research and development initiatives, post news related to partnerships and collaborations, etc.

Screen Shot 2017-06-13 at 09.29.44

In June 2014, the FDA released its social media guidance regarding the presentation of risk and benefit information which prevents pharma companies from marketing their drugs on social media without presenting the risks associated with their use. However, pharma players have found creative and useful ways of attracting and keeping their audiences engaged. Chapeau!

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.
Advertisements

Top Pharma News and Developments that Made Headlines in May

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Merck’s Keytruda got FDA approval to treat genetically ID’d tumors

merck_logo

Merck’s Keytruda was approved by the FDA to treat patients whose cancers have a specific genetic feature, making that the first time the FDA approved a cancer treatment based on a common genetic feature and not on the location where the tumor originated.

Keytruda is used for the treatment of solid tumors that have a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

 

The FDA approved first generic Strattera for the treatment of ADHD

The first generic versions of Strattera  have been approved by the FDA to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

fda

Strattera will be marketed by Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited.

 

Bristol-Myers Squibb entered strategic collaboration with Array BioPharma

bms

Bristol-Myers Squibb has entered a clinical research collaboration with Array BioPharma to test the latter’s investigational MEK inhibitor, binimetinib in combination with its Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen. This could be a treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.

Bristol-Myers Squibb’s Opdivo has recently been accepted for priority review in liver cancer.

 

Sanofi and Regeneron Got FDA Approval for Kevzara

Impression

Sanofi and Regeneron announced FDA approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patientswho have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).

Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), and has been shown to inhibit IL-6R mediated signaling. IL-6 is a cytokine in the body that, in excess and over time, can contribute to the inflammation associated with RA.

In the US, Kevzara will be marketed by Regeneron and Sanofi Genzyme, the specialty care global business unit of Sanofi.

 

Novartis receives FDA approval for expanded use of Zykadia

novartis

The US Food and Drug Administration approved the expanded use of Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

Zykadia first received accelerated approval in 2014 for patients with ALK-positive metastatic NSCLC who progressed on or are intolerant to crizotinib.

In January 2017, the FDA granted Zykadia Breakthrough Therapy designation for the first-line treatment of patients with ALK-positive metastatic NSCLC with metastases to the brain, and Priority Review for first-line ALK-positive metastatic NSCLC.

 

AstraZeneca’s Imfinzi was shown to reduce the risk of disease worsening or death in the Phase III PACIFIC trial

astrazeneca-svg

AstraZeneca and MedImmune, its global biologics research and development arm, revealed positive results for the Phase III PACIFIC trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy combined with radiation therapy.

AstraZeneca also received accelerated approval from the US FDA for Imfinzi in previously treated patients with advanced bladder cancer.

 

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

Top Pharma News and Developments that Made Headlines in April

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

FDA approved Brineura for a specific form of Batten disease

fda

The U.S. Food and Drug Administration approved Brineura as a treatment for a specific form of Batten disease. Being an enzyme replacement therapy, Brineura’s active ingredient (cerliponase alfa) is a recombinant form of human TPP1, the enzyme deficient in patients with CLN2 disease.

Brineura is set to slow loss of walking ability in pediatric patients aged 3 and older suffering from late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.

The FDA granted approval of Brineura to BioMarin Pharmaceutical Inc.

 

Novartis entered clinical trial agreement with Allergan

novartis

Novartis entered into a clinical trial agreement with Allergan to use its FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH) as part of a Phase IIb study.

NASH is known to be one of the biggest triggers of liver diseases leading to liver transplants worldwide. At the moment, there aren’t any approved treatments for NASH.

As part of the agreement, Novartis and Allergan will conduct a Phase IIb clinical trial to assess the safety, efficacy and tolerability of their combines therapies for NASH.

 

Bristol-Myers Squibb enters into separate agreements with Biogen & Roche

bms

Bristol-Myers Squibb entered into two separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds.

Under the agreements, Bristol- Myers Squibb plans to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to Biogen, and BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy, to Roche.

 

Roche’s Tecentriq won FDA OK

roche

Genentech, a unit of Swiss drugmaker Roche Holding AG, got approval from the FDA for its already approved immunotherapy drug, Tecentriq, to treat advanced bladder cancer. The FDA granted Tecentriq an accelerated approval as an initial treatment for patients with advanced bladder cancer who are not eligible for standard cisplatin chemotherapy.

Tecentriq belongs to PD-1 inhibitors drug class. The latter helps the immune system fight cancer by blocking a mechanism used by tumors to escape attack.

 

GlaxoSmithKline’s malaria vaccine Mosquirix to undergo pilot studies in Ghana, Kenya and Malawi

gsk

GlaxoSmithKline’s Mosquirix is set to undergo real-world pilot studies in Ghana, Kenya and Malawi, 3 African countries selected by the World Health Organization, starting next year.

The pilots will enroll babies aged between 5 to 17 months. Besides testing the vaccine’s efficacy, the study will also focus upon whether it’s possible or not to deliver 4 doses in the sub-Saharan areas.

World Health Organization selected the three African countries because of their high malaria rates despite broad use of insecticidal bed nets and well-functioning immunization programs.

 

Takeda partners Harrington Discovery Institute for rare disease therapeutics development

Takeda

Pharma company Takeda has partnered with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, to advance breakthrough therapeutic discoveries in rare diseases.

Under the agreement, Takeda will leverage Harrington Discovery Institute’s established operating model to set up a new programme to advance the development of medicines for rare diseases.

The Harrington programme will assist US MD and PhD researchers to carry out disruptive and transformative research, that may lead to the development of new treatments.
cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

January’s Top Pharma News & Developments

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Johnson & Johnson to acquire Actelion for USD 30 billion

j-j-logo

Johnson & Johnson is set to acquire Swiss biotech company Actelion. The deal is valued at USD 30 billion and will give J&J access to Actelion’s research and development pipeline, as well as medicines for rare diseases.

Under the agreement, Actelion will draw out its research and development unit into a standalone company dubbed R&D NewCo, based in Switzerland, and led by Actelion founder and CEO Jean-Paul Clozel.

J&J will initially hold a 16% stake in R&D NewCo, with rights to an additional 16%.

 

Sanofi, MSD ended vaccines JV

Impression

Sanofi Pasteur, the vaccines division of the multinational pharmaceutical company Sanofi, has ended its vaccines joint venture with MSD, a collaboration that spanned more than 20 years.

The move was first announced in March 2016 and the reason was that both companies wanted to pursue their “distinct growth strategies.”

Throughout its existence, Sanofi Pasteur MSD launched several vaccines onto the European market such as Gardasil and Zostavax.

 

Bristol-Myers Squibb entered clinical collaboration with Janssen

bms

Global biopharmaceutical company Bristol-Myers Squibb has entered a clinical research collaboration with US-based biotechnology company Janssen Biotech.

The aim of the collaboration is to analyse the combination of Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex in Phase 1b/2 clinical studies in multiple myeloma and solid tumors.

In July 2016, Bristol-Myers Squibb and Janssen signed a clinical research collaboration to evaluate Opdivo and Live Attenuated Double-Deleted (LADD) Listerial monocytogenes cancer immunotherapy in patients with non-small cell lung cancer.

 

Merck teamed up with Palantir for faster drug discovery

merck_logo

German multinational pharma company Merck has teamed up with US-based data and analysis software company Palantir to enhance drug discovery and development.

In the beginning, the two companies will partner on three of Merck’s business sectors: healthcare, life sciences, and performance materials.

The exact terms of the deal haven’t yet been disclosed.

 

Novo Nordisk partnered Glooko to develop digital health solutions for patients with diabetes

novo_nordisk-logo

Health platform for diabetes management Glooko has teamed up with Danish multinational pharmaceutical company Novo Nordisk to develop and brand digital health solutions for people with diabetes.

Under the agreement, the companies are set to deliver personalised, digital services to support people with diabetes in what concerns treatment adherence and blood glucose management. The partnership will also make it easier for healthcare professionals to manage patients by leveraging data reporting.

Novo Nordisk’s Digital Health Platform was developed with IBM Watson Health and it aims to improve treatment outcomes.

 

Novartis in USD 1.6 bln deal with Ionis Pharmaceuticals

novartis

Novartis has entered an agreement with US-based biopharmaceutical company Ionis Pharmaceuticals.

Under the deal, Novartis will pay up to USD 1.6 billion to Ionis and its unit Akcea Therapeutics for the rights to two cardiovascular drugs that aim to lower the level of cholesterol-carrying proteins in the blood, thus reducing the risk of cardiovascular diseases. Furthermore, Novartis will invest USD 50 million in either Ionis or Akcea within the first 18 months, as well as payments worth up to USD 1.4 billion if the drugs turn out  successful.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are: